Morgan Stanley’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History
Bought
Maintained
Sold
Other funds holding MTRI
Morgan Stanley's MTRI Position: Q1 2023 in Review
Morgan Stanley held its Mentari Therapeutics, Inc. Common Stock (MTRI) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7772.
Morgan Stanley first reported a position in MTRI in Q4 2020 and has held it in 3 quarters since. The position peaked at $41K in Q1 2021. 4 funds tracked by Wall St. Rank hold MTRI as of Q1 2023.
- Morgan Stanley held 0 shares of Mentari Therapeutics, Inc. Common Stock worth $0 as of Q1 2023.
- Morgan Stanley left its Mentari Therapeutics, Inc. Common Stock share count unchanged in Q1 2023.
- Mentari Therapeutics, Inc. Common Stock made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2023, its #7772 holding.
- Morgan Stanley first reported a position in Mentari Therapeutics, Inc. Common Stock in Q4 2020 and has held it in 3 quarters since.
- Morgan Stanley's Mentari Therapeutics, Inc. Common Stock position peaked at $41K in Q1 2021.
- 4 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.